ResMed Announces Results for the Third Quarter of Fiscal Year 2023

ResMed Announces Results for the Third Quarter of Fiscal Year 2023

April 27, 2023 | Last Trade: US$177.61 3.78 2.17

NYSE: RMD

Medical

Medical Devices

Financial Results

VISIT WEBSITE

Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com

SAN DIEGO, April 27, 2023 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended March 31, 2023.

Third Quarter 2023 Highlights
All comparisons are to the prior year period

Revenue increased by 29% to $1,116.9 million; up 31% on a constant currency basis
Gross margin contracted 150 bps to 55.3%; non-GAAP gross margin contracted 200 bps to 56.1%
Income from operations increased 28%; non-GAAP operating profit up 27%
Operating cash flow of $282.6 million
Diluted earnings per share of $1.58; non-GAAP diluted earnings per share of $1.68

“During the third quarter, we significantly ramped up production and delivery of our cloud-connected flow generator devices to meet ongoing high demand from customers, resulting in strong device sales growth across our global markets,” said Mick Farrell, ResMed’s CEO. “We now have full global availability of our connected AirSense 10 platform, while we continue to ramp production and availability across more geographies of our AirSense 11 platform. The bottom line is this: We can now support global customer demand for CPAP and APAP devices to serve the entire sleep device market. This is great news for physicians, providers, and especially for patients. We also saw very strong growth in our mask and patient interfaces businesses globally, demonstrating a sustainable focus on patient adherence and resupply. Our outside-hospital software-as-a-service business achieved high-single-digit growth organically and reached well into double-digit growth with a full quarter of contribution from our MEDIFOX DAN acquisition that we closed last November. We remain laser-focused on delivering lifesaving therapy solutions and accelerating the adoption of digital health in sleep apnea, COPD, insomnia, and out-of-hospital care. During the last 12 months, we improved over 156 million lives, and we are well on our way to our goal of helping 250 million people sleep better, breathe better, and live higher-quality lives with outside-hospital care in 2025.”

Financial Results and Operating Metrics
Unaudited; $ in millions, except for per share amounts

	Three Months Ended
	March 31, 2023			March 31, 2022			% Change		Constant Currency ^(A)
Revenue	$	1,116.9		$	864.5		29	%	31	%
Gross margin		55.3	%		56.8	%	(3	)
Non-GAAP gross margin ^(B)		56.1	%		58.1	%	(4	)
Selling, general, and administrative expenses		228.5			182.4		25		28
Research and development expenses		76.4			66.8		14		16
Income from operations		300.7			234.3		28
Non-GAAP income from operations ^(B)		321.2			253.0		27
Net income		232.5			179.0		30
Non-GAAP net income ^(B)		247.8			193.3		28
Diluted earnings per share	$	1.58		$	1.22		30
Non-GAAP diluted earnings per share ^(B)	$	1.68		$	1.32		27

	Nine Months Ended
	March 31, 2023			March 31, 2022			% Change		Constant Currency ^(A)
Revenue	$	3,100.9		$	2,663.4		16	%	20	%
Gross margin		56.1	%		56.4	%	(1	)
Non-GAAP gross margin ^(B)		56.8	%		57.6	%	(1	)
Selling, general, and administrative expenses		633.3			544.5		16		21
Research and development expenses		209.5			189.3		11		13
Income from operations		856.6			744.9		15
Non-GAAP income from operations ^(B)		917.5			801.3		15
Net income		667.9			584.4		14
Non-GAAP net income ^(B)		714.3			631.5		13
Diluted earnings per share	$	4.53		$	3.97		14
Non-GAAP diluted earnings per share ^(B)	$	4.85		$	4.30		13

(A)	In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency” basis, which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.
(B)	See the reconciliation of non-GAAP financial measures in the table at the end of the press release.

Discussion of Third Quarter Results

All comparisons are to the prior year period unless otherwise noted

Revenue grew by 31 percent on a constant currency basis, driven by increased demand for our sleep and respiratory care devices as well as reduced competitive supply.
- Revenue in the U.S., Canada, and Latin America, excluding Software-as-a-Service, grew by 32 percent, primarily due to the factors discussed above.
- Revenue in Europe, Asia, and other markets, excluding Software-as-a-Service, grew by 28 percent on a constant currency basis.
- Software-as-a-Service revenue increased by 35 percent, reflecting incremental revenue from our acquisition of MEDIFOX DAN and continued organic growth in our SaaS portfolio.
Gross margin decreased by 150 basis points and non-GAAP gross margin decreased by 200 basis points, mainly due to unfavorable product mix and higher component costs, partially offset by an increase in average selling prices.
Selling, general, and administrative expenses increased by 28 percent on a constant currency basis. SG&A expenses improved to 20.5 percent of revenue in the quarter, compared with 21.1 percent in the same period of the prior year. These changes in SG&A expenses were mainly due to increases in employee-related expenses and increases in travel expenses.
Income from operations increased by 28 percent and non-GAAP income from operations increased by 27 percent.
Net income for the quarter was $232.5 million and diluted earnings per share was $1.58. Non-GAAP net income increased by 28% to $247.8 million, and non-GAAP diluted earnings per share increased by 27% to $1.68, predominantly attributable to strong sales, partially offset by gross margin contraction.
Operating cash flow for the quarter was $282.6 million, compared to net income in the current quarter of $232.5 million and non-GAAP net income of $247.8 million. During the quarter we paid $64.6 million in dividends.

Other Business and Operational Highlights

Announced the retirement of David Pendarvis, Chief Administrative Officer & Global General Counsel, effective June 30, 2023. An internal search for ResMed’s new Global General Counsel is underway and expected to be completed before Pendarvis retires. In parallel, announced the promotion of Amy Wakeham to Chief Communications & Investor Relations Officer, effective April 1, 2023. Wakeham joined ResMed in June 2018 and previously led IR at several other public companies.
Published 2023 Global Sleep Survey as part of National Sleep Awareness Week (March 12-18) and World Sleep Day (March 17). The survey, conducted in January, asked over 20,000 respondents in 12 countries what’s keeping them up at night; survey results aim to build awareness of the critical role good sleep plays in physical and mental health. Of note, 81% of respondents experience one or more symptoms indicating poor sleep quality, despite 64% saying they’re satisfied with the quantity of their sleep.

Dividend program

The ResMed board of directors today declared a quarterly cash dividend of $0.44 per share. The dividend will have a record date of May 11, 2023, payable on June 15, 2023. The dividend will be paid in U.S. currency to holders of ResMed’s common stock trading on the New York Stock Exchange. Holders of CHESS Depositary Interests (“CDIs”) trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be May 10, 2023, for common stockholders and for CDI holders. ResMed has received a waiver from the ASX’s settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from May 10, 2023, through May 11, 2023, inclusive.

Webcast details

ResMed will discuss its third-quarter fiscal year 2023 results on its webcast at 1:30 p.m. U.S. Pacific Time today. The live webcast of the call can be accessed on ResMed’s Investor Relations website at investor.resmed.com. Please go to this section of the website and click on the icon for the “Q3 2023 Earnings Webcast” to register and listen to the live webcast. A replay of the earnings webcast will be accessible on the website and available approximately two hours after the live webcast. In addition, a telephone replay of the conference call will be available approximately three hours after the webcast by dialing +1 877-660-6853 (U.S.) or +1 201-612-7415 (outside U.S.) and entering the passcode 13737758. The telephone replay will be available until May 11, 2023.

About ResMed

At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.

Safe harbor statement

Statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements – including statements regarding ResMed’s projections of future revenue or earnings, expenses, new product development, new product launches, new markets for its products, the integration of acquisitions, litigation, and tax outlook – are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in ResMed’s periodic reports on file with the U.S. Securities & Exchange Commission. ResMed does not undertake to update its forward-looking statements.

Condensed Consolidated Statements of Operations
(Unaudited; $ in thousands, except for per share amounts)

	Three Months Ended						Nine Months Ended
	March 31, 2023			March 31, 2022			March 31, 2023			March 31, 2022

Net revenue	$	1,116,898		$	864,500		$	3,100,936		$	2,663,390

Cost of sales		490,824			362,321			1,340,660			1,128,314
Amortization of acquired intangibles ⁽¹⁾		8,322			10,982			22,001			33,271
Total cost of sales	$	499,146		$	373,303		$	1,362,661		$	1,161,585
Gross profit	$	617,752		$	491,197		$	1,738,275		$	1,501,805

Selling, general, and administrative		228,457			182,401			633,317			544,483
Research and development		76,436			66,801			209,498			189,258
Amortization of acquired intangibles ⁽¹⁾		12,188			7,730			29,701			23,175
Acquisition related expenses		—			—			9,157			—
Total operating expenses	$	317,081		$	256,932		$	881,673		$	756,916
Income from operations	$	300,671		$	234,265		$	856,602		$	744,889

Other income (expenses), net:
Interest income (expense), net	$	(14,964	)	$	(5,462	)	$	(32,436	)	$	(16,770	)
Loss attributable to equity method investments		(183	)		(2,627	)		(5,037	)		(5,927	)
Gain (loss) on equity investments		6,418			(1,735	)		11,506			(527	)
Other, net		(2,564	)		1,878			(5,773	)		729
Total other income (expenses), net		(11,293	)		(7,946	)		(31,740	)		(22,495	)
Income before income taxes	$	289,378		$	226,319		$	824,862		$	722,394
Income taxes		56,878			47,307			156,970			138,018
Net income	$	232,500		$	179,012		$	667,892		$	584,376

Basic earnings per share	$	1.58		$	1.22		$	4.55		$	4.00
Diluted earnings per share	$	1.58		$	1.22		$	4.53		$	3.97
Non-GAAP diluted earnings per share ⁽¹⁾	$	1.68		$	1.32		$	4.85		$	4.30

Basic shares outstanding		146,914			146,240			146,681			145,969
Diluted shares outstanding		147,395			146,962			147,400			147,034

(1)	See the reconciliation of non-GAAP financial measures in the table at the end of the press release.

Condensed Consolidated Balance Sheets
(Unaudited; $ in thousands)

	March 31, 2023			June 30, 2022
Assets
Current assets:
Cash and cash equivalents	$	227,894		$	273,710
Accounts receivable, net		686,264			575,950
Inventories		1,011,269			743,910
Prepayments and other current assets		412,388			337,908
Total current assets	$	2,337,815		$	1,931,478
Non-current assets:
Property, plant, and equipment, net	$	528,778		$	498,181
Operating lease right-of-use assets		127,508			132,314
Goodwill and other intangibles, net		3,353,302			2,282,386
Deferred income taxes and other non-current assets		366,476			251,494
Total non-current assets	$	4,376,064		$	3,164,375
Total assets	$	6,713,879		$	5,095,853
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	161,896		$	159,245
Accrued expenses		347,354			344,722
Operating lease liabilities, current		23,129			21,856
Deferred revenue		141,043			108,667
Income taxes payable		78,368			44,893
Short-term debt		9,901			9,916
Total current liabilities	$	761,691		$	689,299
Non-current liabilities:
Deferred revenue	$	108,875		$	95,455
Deferred income taxes		113,015			9,714
Operating lease liabilities, non-current		115,090			120,453
Other long-term liabilities		69,553			5,974
Long-term debt		1,575,963			765,325
Long-term income taxes payable		37,183			48,882
Total non-current liabilities	$	2,019,679		$	1,045,803
Total liabilities	$	2,781,370		$	1,735,102
Stockholders’ equity
Common stock	$	588		$	586
Additional paid-in capital		1,728,997			1,682,432
Retained earnings		4,088,057			3,613,736
Treasury stock		(1,623,256	)		(1,623,256	)
Accumulated other comprehensive income		(261,877	)		(312,747	)
Total stockholders’ equity	$	3,932,509		$	3,360,751
Total liabilities and stockholders’ equity	$	6,713,879		$	5,095,853

Condensed Consolidated Statements of Cash Flows
(Unaudited; $ in thousands)

	Three Months Ended						Nine Months Ended
	March 31, 2023			March 31, 2022			March 31, 2023			March 31, 2022
Cash flows from operating activities:
Net income	$	232,500		$	179,012		$	667,892		$	584,376
Adjustment to reconcile net income to cash provided by operating activities:
Depreciation and amortization		44,356			42,306			118,396			122,198
Amortization of right-of-use assets		8,434			9,302			23,967			26,636
Stock-based compensation costs		17,832			15,860			51,215			49,265
Loss attributable to equity method investments		183			2,627			5,037			5,927
(Gain) loss on equity investment		(6,418	)		1,735			(11,506	)		527
Changes in operating assets and liabilities:
Accounts receivable, net		(12,629	)		15,689			(88,452	)		98,158
Inventories, net		(21,974	)		(70,227	)		(255,091	)		(209,476	)
Prepaid expenses, net deferred income taxes and other current assets		(19,961	)		(106,588	)		(86,607	)		(127,977	)
Accounts payable, accrued expenses, income taxes payable and other		40,240			27,722			31,012			(277,973	)
Net cash provided by operating activities	$	282,563		$	117,438		$	455,863		$	271,661
Cash flows from investing activities:
Purchases of property, plant, and equipment		(28,817	)		(48,445	)		(85,223	)		(106,192	)
Patent registration and acquisition costs		(2,406	)		(3,712	)		(10,043	)		(17,449	)
Business acquisitions, net of cash acquired		—			—			(1,011,225	)		(35,915	)
Purchases of investments		(12,597	)		(4,250	)		(29,729	)		(16,614	)
Proceeds from exits of investments		3,937			6,802			3,937			6,802
(Payments) / proceeds on maturity of foreign currency contracts		11,780			110			18,961			(5,309	)
Net cash used in investing activities	$	(28,103	)	$	(49,495	)	$	(1,113,322	)	$	(174,677	)
Cash flows from financing activities:
Proceeds from issuance of common stock, net		983			2,814			25,649			26,269
Taxes paid related to net share settlement of equity awards		(584	)		(2,253	)		(30,297	)		(52,278	)
Payments of business combination contingent consideration		(316	)		—			(316	)		—
Proceeds from borrowings, net of borrowing costs		—			—			1,070,000			160,000
Repayment of borrowings		(215,000	)		—			(260,000	)		(136,000	)
Dividends paid		(64,640	)		(61,418	)		(193,571	)		(183,853	)
Net cash (used in) / provided by financing activities	$	(279,557	)	$	(60,857	)	$	611,465		$	(185,862	)
Effect of exchange rate changes on cash	$	(208	)	$	207		$	178		$	(4,631	)
Net increase / (decrease) in cash and cash equivalents		(25,305	)		7,293			(45,816	)		(93,509	)
Cash and cash equivalents at beginning of period		253,199			194,476			273,710			295,278
Cash and cash equivalents at end of period	$	227,894		$	201,769		$	227,894		$	201,769

Reconciliation of Non-GAAP Financial Measures
(Unaudited; $ in thousands, except for per share amounts)

The measures “non-GAAP gross profit” and “non-GAAP gross margin” exclude amortization expense from acquired intangibles related to cost of sales and are reconciled below:

	Three Months Ended						Nine Months Ended
	March 31, 2023			March 31, 2022			March 31, 2023			March 31, 2022

Revenue	$	1,116,898		$	864,500		$	3,100,936		$	2,663,390

GAAP cost of sales	$	499,146		$	373,303		$	1,362,661		$	1,161,585
Less: Amortization of acquired intangibles ^(A)		(8,322	)		(10,982	)		(22,001	)		(33,271	)
Non-GAAP cost of sales	$	490,824		$	362,321		$	1,340,660		$	1,128,314

GAAP gross profit	$	617,752		$	491,197		$	1,738,275		$	1,501,805
GAAP gross margin		55.3	%		56.8	%		56.1	%		56.4	%
Non-GAAP gross profit	$	626,074		$	502,179		$	1,760,276		$	1,535,076
Non-GAAP gross margin		56.1	%		58.1	%		56.8	%		57.6	%

The measure “non-GAAP income from operations” is reconciled with GAAP income from operations below:

	Three Months Ended				Nine Months Ended
	March 31, 2023		March 31, 2022		March 31, 2023		March 31, 2022

GAAP income from operations	$	300,671	$	234,265	$	856,602	$	744,889
Amortization of acquired intangibles—cost of sales ^(A)		8,322		10,982		22,001		33,271
Amortization of acquired intangibles—operating expenses ^(A⁾		12,188		7,730		29,701		23,175
Acquisition-related expenses ^(A)		—		—		9,157		—
Non-GAAP income from operations	$	321,181	$	252,977	$	917,461	$	801,335

Reconciliation of Non-GAAP Financial Measures
(Unaudited; $ in thousands, except for per share amounts)

The measures “non-GAAP net income” and “non-GAAP diluted earnings per share” are reconciled with GAAP net income and GAAP diluted earnings per share in the table below:

	Three Months Ended				Nine Months Ended
	March 31, 2023		March 31, 2022		March 31, 2023		March 31, 2022

GAAP net income	$	232,500	$	179,012	$	667,892	$	584,376
Amortization of acquired intangibles—cost of sales, net of tax ^(A)		6,207		8,374		16,531		25,373
Amortization of acquired intangibles—operating expenses, net of tax ^(A)		9,090		5,894		22,317		17,673
Acquisition related expenses, net of tax ^(A)		—		—		7,527		—
Reserve for disputed tax position ^(A)		—		—		—		4,111
Non-GAAP net income ^(A)	$	247,797	$	193,280	$	714,267	$	631,533

GAAP diluted shares outstanding		147,395		146,962		147,400		147,034
GAAP diluted earnings per share	$	1.58	$	1.22	$	4.53	$	3.97
Non-GAAP diluted earnings per share ^(A)	$	1.68	$	1.32	$	4.85	$	4.30

(A)

ResMed adjusts for the impact of the amortization of acquired intangibles, acquisition related expenses and the reserve for disputed tax positions from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance.

ResMed believes that non-GAAP diluted earnings per share is an additional measure of performance that investors can use to compare operating results between reporting periods. ResMed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. ResMed believes this information provides investors better insight when evaluating ResMed’s performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP.

Revenue by Product and Region
(Unaudited; $ in millions, except for per share amounts)

	Three Months Ended
	March 31, 2023		^(A)	March 31, 2022		^(A)	% Change		Constant Currency^(B)
U.S., Canada, and Latin America
Devices	$	372.1		$	250.8		48	%
Masks and other		257.1			224.7		14
Total U.S., Canada and Latin America	$	629.1		$	475.4		32

Combined Europe, Asia, and other markets
Devices	$	235.8		$	182.3		29	%	36	%
Masks and other		115.2			105.6		9		15
Total Combined Europe, Asia and other markets	$	351.0		$	287.9		22		28

Global revenue
Total Devices	$	607.9		$	433.1		40	%	43	%
Total Masks and other		372.2			330.3		13		15
Total Sleep and Respiratory Care	$	980.1		$	763.4		28		31

Software-as-a-Service		136.8			101.1		35
Total	$	1,116.9		$	864.5		29		31

	Nine Months Ended
	March 31, 2023		^(A)	March 31, 2022		^(A)	% Change		Constant Currency ^(B)
U.S., Canada, and Latin America
Devices	$	1,057.1		$	771.5		37	%
Masks and other		765.4			681.8		12
Total U.S., Canada and Latin America	$	1,822.5		$	1,453.3		25

Combined Europe, Asia, and other markets
Devices	$	611.1		$	608.3		Nil%		9	%
Masks and other		307.9			304.2		1		12
Total Combined Europe, Asia and other markets	$	919.0		$	912.4		1		10

Global revenue
Total Devices	$	1,668.3		$	1,379.7		21	%	25	%
Total Masks and other		1,073.3			986.0		9		12
Total Sleep and Respiratory Care	$	2,741.5		$	2,365.7		16		20

Software-as-a-Service		359.4			297.7		21
Total	$	3,100.9		$	2,663.4		16		20

(A)	Totals and subtotals may not add due to rounding.
(B)	In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency basis,” which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.

For investors	For media
+1 858-836-5000	+1 858-836-6798
This email address is being protected from spambots. You need JavaScript enabled to view it.	This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Last Trade:	US$177.61
Daily Change:	3.78 2.17
Daily Volume:	1,441,413
Market Cap:	US$26.120B

March 06, 2024 Introducing the AirFit F40: Experience Unprecedented Freedom with the Comfort and Optimized Seal Performance of ResMed’s Smallest Full-Face CPAP Mask February 12, 2024 ResMed’s New AirCurve™ 11 Bilevel Devices Enable Healthcare Providers to Make Informed Decisions about Care, Deliver Personalized Support, and Drive Positive Therapy Outcomes for Patients with Sleep Apnea January 24, 2024 ResMed Announces Results for the Second Quarter of Fiscal Year 2024 December 27, 2023 ResMed Announces Participation in the 42nd Annual J.P. Morgan Healthcare Conference October 26, 2023 ResMed Announces Results for the First Quarter of Fiscal Year 2024 LOAD MORE NEWS

Featured Stock

Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE